{
    "organizations": [],
    "uuid": "ffd21d1d1693d1bf3ef267b7774a720acbeb23b4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-catalyst-biosciences-announces-man/brief-catalyst-biosciences-announces-manufacturing-agreement-with-agc-biologics-for-subcutaneous-factor-ix-product-cb-2679d-idUSFWN1QG0OX",
    "ord_in_thread": 0,
    "title": "BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Catalyst Biosciences Inc:\n* CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D\n* CATALYST BIOSCIENCES INC - PLAN TO INITIATE A PHASE 2B STUDY OF CB 2679D IN INDIVIDUALS WITH SEVERE HEMOPHILIA B IN Q3 OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-26T21:12:00.000+02:00",
    "crawled": "2018-02-27T14:39:16.127+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "catalyst",
        "bioscience",
        "inc",
        "catalyst",
        "bioscience",
        "announces",
        "manufacturing",
        "agreement",
        "agc",
        "biologics",
        "subcutaneous",
        "factor",
        "ix",
        "product",
        "cb",
        "2679d",
        "catalyst",
        "bioscience",
        "inc",
        "plan",
        "initiate",
        "phase",
        "2b",
        "study",
        "cb",
        "2679d",
        "individual",
        "severe",
        "hemophilia",
        "b",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}